

Universal Biosensors, Inc.  
ARBN 121 559 993

1 Corporate Avenue  
Rowville Victoria 3178  
Australia

Telephone +61 3 9213 9000  
Facsimile +61 3 9213 9099  
Email [info@universalbiosensors.com](mailto:info@universalbiosensors.com)  
[www.universalbiosensors.com](http://www.universalbiosensors.com)



ASX Announcement  
19 January 2018

ASX: UBI

## EXPIRY OF UNLISTED OPTIONS

The Company wishes to advise of the following changes in its securities:

- Lapsing of the following options without exercise:
  - 30,000 Options (A\$0.89, 16 March 2018) – equivalent to 30,000 CDIs
  - 80,000 Options (A\$0.94, 28 June 2019) – equivalent to 80,000 CDIs
  - 80,000 Options (A\$1.72, 9 November 2019) – equivalent to 80,000 CDIs
  - 20,000 Options (A\$0.89, 17 November 2018) – equivalent to 20,000 CDIs
  - 20,000 Options (A\$1.09, 12 November 2019) – equivalent to 20,000 CDIs
  - 20,000 Options (A\$0.49, 11 December 2020) – equivalent to 20,000 CDIs
  - 13,332 Options (A\$0.23, 29 January 2022) – equivalent to 13,332 CDIs
  - 273,000 Options (A\$0.50, 20 April 2023) – equivalent to 273,000 CDIs

The capital structure of the Company following the release of the unquoted securities is as follows:

### Quoted Securities

176,005,801 Ordinary Fully Paid Shares (equivalent to 176,005,801 CDIs)

### Unquoted Securities

Number	Instrument	Exercise Price	Expiry Date	CDI Equivalent
492,749	Restricted Shares	N/A	N/A	492,749
590,000	Employee Options	\$0.89	16-Mar-18	590,000
102,000	Employee Options	\$0.70	19-Aug-18	102,000
8,000	Employee Options	\$0.50	16-Feb-19	8,000
33,334	Employee Options	\$0.00	14-May-19	33,334
388,334	Employee Options	\$0.00	28-Jun-19	388,334
588,667	Employee Options	\$0.94	28-Jun-19	588,667
985,000	Employee Options	\$1.72	9-Nov-19	985,000
138,000	Employee Options	\$1.37	9-Mar-18	138,000
66,000	Employee Options	\$1.00	21-Sep-18	66,000
190,000	Employee Options	\$0.89	17-Nov-18	190,000
100,000	Employee Options	\$0.00	17-Nov-18	100,000
50,000	Employee Options	\$0.75	12-Mar-19	50,000
12,000	Employee Options	\$0.73	13-Sep-19	12,000
217,500	Employee Options	\$1.09	12-Nov-19	217,500
100,000	Employee Options	\$0.00	12-Nov-19	100,000
24,000	Employee Options	\$0.79	11-Mar-20	24,000



Universal Biosensors

30,000	Employee Options	\$0.71	12-Nov-19	30,000
222,500	Employee Options	\$0.49	11-Dec-20	222,500
160,000	Employee Options	\$0.00	11-Dec-20	160,000
80,000	Employee Options	\$0.17	13-Aug-21	80,000
255,832	Employee Options	\$0.23	29-Jan-22	255,832
160,000	Employee Options	\$0.00	29-Jan-22	160,000
309,166	Employee Options	\$0.45	13-Dec-22	309,166
7,878,000	Employee Options	\$0.50	20-Apr-23	7,878,000
211,500	Employee Options	\$0.33	27-Dec-23	211,500
2,281,500	Employee Options	\$0.50	27-Feb-24	2,281,500
1,600,000	Employee Options	\$0.50	23-Oct-22	1,600,000
2,700,000	Employee Options	\$0.60	23-Oct-22	2,700,000
3,300,000	Employee Options	\$0.80	23-Oct-22	3,300,000
4,500,000	Warrants	\$1.00	19-Dec-20	4,500,000

**-Ends-**

---

Enquiries:  
Mr. Salesh Balak: 03 9213 9000

### **About Universal Biosensors**

For additional information regarding Universal Biosensors, refer to: <http://www.universalbiosensors.com/>. Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.

### **Forward-Looking Statements**

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.